The present disclosure features anti-TIGIT (T-cell immunoreceptor with lg and ITIM domains) antibodies that specifically bind to a unique human TIGIT epitope comprising Ser78, Ser80 and Lys82 and uses thereof in treating or delaying progression of cancer or an immune related disease, or enhancing an immune response in a subject in need thereof.